Muscular Dystrophy Therapy Falls Short. Or Did It? - The American Spectator
It wasn’t dismal news for sufferers of Duchenne Muscular Dystrophy (DMD). It does appear that Elevidys can slow the disease's progression.
Stay updated with breaking news from Solid Biosciences. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
It wasn’t dismal news for sufferers of Duchenne Muscular Dystrophy (DMD). It does appear that Elevidys can slow the disease's progression.
By Stephen Nakrosis Shares of Solid Biosciences were trading higher in Tuesday's after-hours market, following news the U.S. Food and Drug Administration...
Solid Biosciences Inc. (NASDAQ:SLDB – Get Free Report) was the target of a large decrease in short interest in the month of October. As of October 15th, there was short interest totalling 21,500 shares, a decrease of 27.4% from the September 30th total of 29,600 shares. Based on an average trading volume of 23,700 shares, […]
/PRNewswire/ -- DelveInsight's Pompe Disease Market Insights report includes a comprehensive understanding of current treatment practices, Pompe disease...
Joe Lewis must wait until at least January for his next court hearing for allegedly “orchestrating a brazen insider trading scheme” that involved passing non-public information to his girlfriend and two private pilots. The British billionaire, who founded Tottenham Hotspur’s controlling company ENIC Sports Inc, was indicted in July. He pleaded not guilty to all 16 counts of securities fraud in a Manhattan federal court on July 25 and his bail was set at $300million, secured against his 98-metre super yacht and aircraft. Lewis, 86, is not due back in court until the new year. The case...